Source: International Congress 2017 – How to manage difficult tuberculosis cases: diagnosis and treatment
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Luigi Ruffo Codecasa (Milan, Italy). The drug armamentarium for MDR-TB cases. International Congress 2017 – How to manage difficult tuberculosis cases: diagnosis and treatment

Member's Comments

No comment yet.

Related content which might interest you: MDR-TB and XDR-TB: drug resistance and treatment outcomes Source: Eur Respir J 2009; 34: 778 Year: 2009 New and repurposed drugs for MDR-TB patients Source: International Congress 2017 – PG2 Multidrug-resistant tuberculosis management in settings with a low tuberculosis incidence  Year: 2017 Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Bacteriological conversion in XDR-TB and RR-TB patients with fluoroquinolone resistance treated with and without new and repurposed anti-TB drugs in Azerbaijan prisons Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 Linezolid in the treatment of patients with MDR TB and XDR TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Novel drug regimens against MDR-TB Source: International Congress 2016 – The problem of multidrug-resistant tuberculosis Year: 2016 MDR-TB treatment in prison setting Source: Annual Congress 2007 - Tuberculosis control in the penitentiary and civilian sector Year: 2007 Experience of Bedaquiline use in treatment of XDR-TB patients Source: International Congress 2017 – TB: diagnosis, severity and practical management Year: 2017 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002 MDR-TB guidelines: what is new on clinical management Source: ERS Webinar 2020: MDR-TB guidelines: what is new on clinical management Year: 2020 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use Source: Eur Respir J, 50 (1) 1700311; 10.1183/13993003.00311-2017 Year: 2017 Is standardized treatment appropriate for non-XDR multiple drug resistant TB? Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 The experience of complex treatment of XDR-TB patients Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009 Peripheral neuropathy in XDR-TB patients on second line anti-tubercular therapy Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Outcomes for multidrug-resistant tuberculosis patients with and without resistance to fluoroquinolones and second-line injectable drugs: A meta-analysis of individual patient data Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012